Gilead Amends Arcus Biosciences Stake, Signals Ownership Change

TL;DR

**Gilead just updated its Arcus Biosciences stake, watch for potential strategic shifts!**

AI Summary

Gilead Sciences, Inc. filed an amended Schedule 13D on January 31, 2024, updating its beneficial ownership in Arcus Biosciences, Inc. This amendment, triggered by an event on January 29, 2024, indicates a change in Gilead's stake in Arcus's Common Stock, par value $0.0001. This matters to investors because Gilead is a major stakeholder, and any changes in its ownership or intentions could signal shifts in its strategic partnership or future plans for Arcus, potentially impacting Arcus's stock valuation.

Why It Matters

This filing shows an update to Gilead's significant ownership in Arcus Biosciences, which could influence Arcus's strategic direction and market perception.

Risk Assessment

Risk Level: medium — Changes in a major investor's stake can introduce uncertainty or signal future strategic moves, impacting the stock's volatility.

Analyst Insight

Investors should monitor subsequent filings or press releases from Gilead or Arcus for details on the specific nature of the change in ownership or any related strategic announcements, as this filing only indicates an update occurred without providing specifics on the change itself.

Key Players & Entities

• Gilead Sciences, Inc. (company) — the filing person and major investor in Arcus Biosciences, Inc.
• Arcus Biosciences, Inc. (company) — the subject company in which Gilead Sciences, Inc. holds a stake
• $0.0001 (dollar_amount) — par value of Arcus Biosciences' Common Stock
• January 29, 2024 (date) — date of the event requiring the filing of this statement
• January 31, 2024 (date) — filing date of the SC 13D/A

FAQ

From the Filing

0001104659-24-008866.txt : 20240131 0001104659-24-008866.hdr.sgml : 20240131 20240131165844 ACCESSION NUMBER: 0001104659-24-008866 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20240131 DATE AS OF CHANGE: 20240131 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Arcus Biosciences, Inc. CENTRAL INDEX KEY: 0001724521 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473898435 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-90423 FILM NUMBER: 24583755 BUSINESS ADDRESS: STREET 1: 3928 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: (510) 694-6200 MAIL ADDRESS: STREET 1: 3928 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 SC 13D/A 1 tm244278d1_sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* ARCUS BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03969F109 (CUSIP Number) Gilead Sciences, Inc. 333 Lakeside Drive Foster City, California 94404 650-574-3000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) January 29, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨ . Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7(b) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“ Act ”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13D CUSIP No. 03969F109 Page 2 of 8 Pages 1 NAME OF REPORTING PERSONS Gilead Sciences, Inc. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨ (b) ¨ 3 SEC USE ONLY 4 SOURCE OF FUNDS (See Instructions) OO 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨ 6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 31,532,781 (1) 8 SHARED VOTING POWER 0 9 SOLE DISPOSITIVE POWER 31,532,781 (1) 10 SHARED DISPOSITIVE POWER 0 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 31,532,781 (1) 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) ¨ 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 35% (2) 14 TYPE OF REPORTING PERSON (See Instructions) CO (1) Consists of (i) 2,200